ScottWWoodsMD

Psychiatry • New Haven, CT

Professor, Psychiatry, Yale University School of Medicine

Join to view full profile

Dr. Woods is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Woods' full profile

Already have an account?

Office
34 Park St
# Connecti
New Haven, CT 06519
Phone+1 203-974-7417

Fax+1 203-974-7413

Education & Training

Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1980 - 1984
Baylor College of MedicineClass of 1978

Certifications & Licensure

CT State Medical License 1984 - 2025
TX State Medical License 1979 - 1984
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Rapid Benzodiazepine Detoxification Using Flumazenil - 1 Start of enrollment: 1993 Jan 01
Completed
Phase 2
Treatment of Panic Disorder: Long Term Strategies Start of enrollment: 1999 Feb 01
Completed
Phase 3
Prevalence of Diabetes Mellitus Among Patients Treated With Atypical and Conventional Antipsychotics
Completed
Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia
Completed
Phase 4
Aripiprazole Treatment of Prodromal Patients Start of enrollment: 2004 Feb 01
Completed
Phase 2, Phase 3
Glycine Treatment of Prodromal Symptoms Start of enrollment: 2002 Jul 01
Completed
Phase 2
Enhancing the Prospective Prediction of Psychosis Start of enrollment: 2003 Aug 01
Completed
Glycine vs Placebo for the Schizophrenia Prodrome Start of enrollment: 2006 Mar 01
Completed
Phase 2, Phase 3
Specialized Treatment Early in Psychosis (STEP) Start of enrollment: 2006 Mar 01
Completed
Not Applicable
Ethyl-EPA Treatment of Prodromal Patients Start of enrollment: 2001 Sep 01
Completed
Phase 2, Phase 3
Ziprasidone in the Psychosis Prodrome Start of enrollment: 2008 Mar 01
Completed
Phase 2
Huperzine for Cognitive and Functional Impairment in Schizophrenia Start of enrollment: 2010 Mar 01
Completed
Phase 2
Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis Start of enrollment: 2015 Jan 01
Terminated
Early Phase 1
STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S. Start of enrollment: 2014 Feb 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Robust Brain Correlates of Cognitive Performance in Psychosis and Its Prodrome.
Heather Burrell Ward, Adam Beermann, Jing Xie, Gulcan Yildiz, Karlos Manzanarez Felix
Biological Psychiatry. 2025-01-15
Unique Functional Neuroimaging Signatures of Genetic Versus Clinical High Risk for Psychosis.
Charles H Schleifer, Sarah E Chang, Carolyn M Amir, Kathleen P O'Hora, Hoki Fung
Biological Psychiatry. 2025-01-15
A Computational Account of the Development and Evolution of Psychotic Symptoms.
Albert Powers, Phillip A Angelos, Alexandria Bond, Emily Farina, Carolyn Fredericks
Biological Psychiatry. 2025-01-15

Journal Articles

Use of Machine Learning to Determine Deviance in Neuroanatomical Maturity Associated with Future Psychosis in Youths at Clinically High Risk
Daniel H Mathalon, Thomas McGlashan, Scott W Woods, Diana Perkins, Ming Tsuang, Carrie E Bearden, Kristin Cadenhead, JAMA

Press Mentions

Feinstein Institutes Researchers Help Lead $52M Study of Schizophrenia in High-Risk YouthNovember 16th, 2020
Accelerating Science to Advance Early Interventions for SchizophreniaOctober 30th, 2020
Scientists Awarded $52M NIH Grant to Study Schizophrenia Cause and EffectSeptember 15th, 2020
Join now to see all

Grant Support

8/8-Predictors And Mechanisms Of Conversion To PsychosisNational Institute Of Mental Health2008–2012
Huperzine For Cognitive And Functional Impairment In SchizophreniaNational Institute Of Mental Health2008–2010
Enhancing The Prospective Prediction Of PsychosisNational Institute Of Mental Health2003–2007
Tardive Dyskinesia Incidence And Atypical AntipsychoticNational Institute Of Mental Health2001–2004
Treatment Of Panic Disorder--Long Term StrategiesNational Institute Of Mental Health1999–2003
Tardive Dyskinesia Incidence And Atypical AntipsychoticsNational Institute Of Mental Health2000
Atypical Antipsychotic Medications--Outcomes And CostsNational Institute Of Mental Health1997–2000
Glutaminergic Agents For Cocaine AbuseNational Institute On Drug Abuse1996–1998
CT DMH Yale Medication Effectiveness Research ProgramNational Institute Of Mental Health1994–1998
Multictr Comparative Treatment Study Of Panic DisorderNational Institute Of Mental Health1996
Multi-Ctr Comparative Treatment Study Of Panic DisorderNational Institute Of Mental Health1995
Treatment Study Of Panic DisorderNational Institute Of Mental Health1994
Rapid Benzodiazepine Detoxification Using FlumazenilNational Institute On Drug Abuse1993–1994
Multi-Ctr Comparative Treatment Study Of Panic DisorderNational Institute Of Mental Health1990–1993
Effects Of Yohimbine On RCBF In Panic DisorderNational Institute Of Mental Health1989